Kathy Keimig, MD
Family Medicine · Gulfport, MSNPI 1760564801
Payments from drug & device makers
Across 625 payments — averaging $32.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$10K
- AbbVie$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Pfizer$706
- plus $3K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 58 | $10,021 |
| AbbVie(2 entities) | 154 | $2,318 |
| AstraZeneca | 55 | $1,446 |
| Novo Nordisk | 69 | $1,170 |
| Lilly USA, LLC | 67 | $1,073 |
| Pfizer | 37 | $706 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $495 |
| Johnson & Johnson | 12 | $476 |
| Astellas Pharma US Inc | 20 | $305 |
| GSK | 11 | $267 |
| Abbott | 11 | $258 |
| Boehringer Ingelheim | 15 | $246 |
| Merck | 11 | $145 |
| Axsome Therapeutics, Inc. | 6 | $144 |
| Sanofi-aventis U.S. LLC | 7 | $134 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $129 |
| Esperion Therapeutics, Inc. | 5 | $80 |
| Exact Sciences | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $71 |
| Shire North American Group Inc | 4 | $68 |
| Medtronic | 3 | $66 |
| Mylan Specialty L.p. | 4 | $62 |
| Novartis | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| IBSA Pharma Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Apria Healthcare LLC | 1 | $14 |
How this compares
$20,102 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family medicine in Gulfport
- Paul MatherneGulfport$14.4M
- Sean KerbyGulfport$6.6M
- Jonathan HamiltonGulfport$16K
- Dimitrios DimitriadesGulfport$13K
- Steven SchepensGulfport$12K
- Matthew BosargeGulfport$10K
- Timothy QuinnRidgeland$8M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.